FOR PRACTIONERS
The Global clinicians currently using the ENDOSURE TEST* call it a game changer! It is the only Non-Invasive, 30-Minute,¹ Highly Accurate Diagnostic Test that detects the presence of Endometriosis anywhere in the anatomy regardless of age, disease state or other concurrent diseases.
The endo test is also used to conduct post treatment follow-up regardless of treatment type.
The test can be performed during the initial encounter for patients presenting with pelvic or menstrual pain as well as other abdominal symptoms.
The EndoSure Test*
The endo test is easy to perform, and can be performed by a technician and provides definitive data in 30 minutes to confirm or eliminate the presence of endometriosis, whether in the abdominal/pelvic area as well as the chest, spine, brain or other anatomical regions.
Download our Brochure
During the Electrogastrogram (EGG)/Electroviscerogram (EVG) portion of the test, the proprietary TRICORDER-3L collects data on very specific myoelectrical activity from the patient’s gastrointestinal tract. Research has shown that the neurotransmitters secreted by endometriosis tissue uncouple normal myoelectrical control in the gastrointestinal tract, resulting in idiosyncratic abnormally high frequency activity, producing a unique myoelectric signal.² Calculations, based on published research,³ are conducted by the EndoSure support software using this data. The resulting information can be used to support for rapid diagnosis of endometriosis during the first patient encounter.
ABOUT US
ENDOSURE, INC. offers the only non-invasive, 30-minute, highly accurate diagnosis test for endometriosis that not only fills the gap, but addresses the vacuum in this area of women’s health care.*
© February 2025 ENDOSURE, INC. All rights reserved
1. Approximately 15-20 minutes of patient preparation time may be required prior to performing the test.
2. Mathias JR, Franklin R, Quast DC, Fraga N, Loftin CA, Yates L, Harrison V. Relation of endometriosis and neuromuscular disease of the gastrointestinal tract: new insights. Fertil Steril. 1998 Jul;70(1):81-8.
3. i. Noar M, Mathias J, Kolatkar A. Gastrointestinal Myoelectrical Activity (GIMA) Biomarker for Noninvasive Diagnosis of Endometriosis. J Clin Med. 2024 May 13;13(10):2866. doi: 10.3390/jcm13102866. PMID: 38792407; PMCID: PMC11122642.
4. Zondervan, K.T.; Becker, C.M.; Koga, K.; Missmer, S.A.; Taylor, R.N.; Viganò, P. Endometriosis. Nat. Rev. Dis. Primers. 2018:4-9.
5. 1. Noar M, Mathias J, Kolatkar A. Validation of New GIMA Biomarker Signature of Endometriosis - Interim Data: Research Article. TechRxiv. August 26, 2024. DOI: 10.22541/au.172469630.08159498/v1
6. 1. Kitsantas P, Benson KN, Al-Farauki S, Knecht MK, Hennekens CH, et al. (2024) Emerging Diagnostic Tools for the Early Diagnosis of Endometriosis. J Reprod Med Gynecol Obstet 9: 171.
DISCLAIMER: THE ENDOSURE TEST IS A DIAGNOSTIC TOOL INTENDED TO INFORM AND ENHANCE A HEALTHCARE PROVIDER'S DECISION-MAKING PROCESS, WHICH IS INDIVIDUALIZED FOR EACH PATIENT'S CIRCUMSTANCES AND TAKE INTO ACCOUNT THE FULL SCOPE OF MEDICAL DATA AND INFORMATION AVAILABLE TO THE PROVIDER. THE ENDOSURE TEST IS NOT INTENDED TO SUBSTITUTE, REPLACE, OVERRULE, OR DIRECT A HEALTHCARE PROVIDER’S JUDGMENT.
* USA CUSTOMERS: EndoSure is currently available for research in the USA use only and not clinical use.